CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease
Abstract Inflammatory bowel disease (IBD) has emerged a global disease and the ascending incidence and prevalence is accompanied by elevated morbidity, mortality, and substantial healthcare system costs. However, the current typical one‐size‐fits‐all therapeutic approach is suboptimal for a substant...
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Wiley
2021-02-01
|
| Collection: | Clinical and Translational Medicine |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1002/ctm2.339 |